Your browser doesn't support javascript.
loading
Immune responses during COVID-19 breakthrough cases in vaccinated children and adolescents.
Rivera-Pérez, Daniela; Méndez, Constanza; Diethelm-Varela, Benjamín; Melo-González, Felipe; Vázquez, Yaneisi; Meng, Xing; Xin, Qianqian; Fasce, Rodrigo A; Fernández, Jorge; Mora, Judith; Ramirez, Eugenio; Acevedo, Mónica L; Valiente-Echeverría, Fernando; Soto-Rifo, Ricardo; Grifoni, Alba; Weiskopf, Daniela; Sette, Alessandro; Astudillo, Patricio; Le Corre, Nicole; Abarca, Katia; Perret, Cecilia; González, Pablo A; Soto, Jorge A; Bueno, Susan M; Kalergis, Alexis M.
Affiliation
  • Rivera-Pérez D; Millennium Institute on Immunology and Immunotherapy, Santiago, Chile.
  • Méndez C; Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Diethelm-Varela B; Millennium Institute on Immunology and Immunotherapy, Santiago, Chile.
  • Melo-González F; Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Vázquez Y; Millennium Institute on Immunology and Immunotherapy, Santiago, Chile.
  • Meng X; Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Xin Q; Millennium Institute on Immunology and Immunotherapy, Santiago, Chile.
  • Fasce RA; Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Fernández J; Departamento de Ciencias Biológicas, Facultad de Ciencias de la Vida, Universidad Andrés Bello, Santiago, Chile.
  • Mora J; Millennium Institute on Immunology and Immunotherapy, Santiago, Chile.
  • Ramirez E; Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Acevedo ML; Sinovac Biotech, Beijing, China.
  • Valiente-Echeverría F; Sinovac Biotech, Beijing, China.
  • Soto-Rifo R; Departamento de Laboratorio Biomédico, Instituto de Salud Pública de Chile, Santiago, Chile.
  • Grifoni A; Departamento de Laboratorio Biomédico, Instituto de Salud Pública de Chile, Santiago, Chile.
  • Weiskopf D; Departamento de Laboratorio Biomédico, Instituto de Salud Pública de Chile, Santiago, Chile.
  • Sette A; Departamento de Laboratorio Biomédico, Instituto de Salud Pública de Chile, Santiago, Chile.
  • Astudillo P; Millennium Institute on Immunology and Immunotherapy, Santiago, Chile.
  • Le Corre N; Laboratorio de Virología Molecular y Celular, Programa de Virología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile.
  • Abarca K; Millennium Institute on Immunology and Immunotherapy, Santiago, Chile.
  • Perret C; Laboratorio de Virología Molecular y Celular, Programa de Virología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile.
  • González PA; Millennium Institute on Immunology and Immunotherapy, Santiago, Chile.
  • Soto JA; Laboratorio de Virología Molecular y Celular, Programa de Virología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile.
  • Bueno SM; Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA, United States.
  • Kalergis AM; Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA, United States.
Front Immunol ; 15: 1372193, 2024.
Article in En | MEDLINE | ID: mdl-38812507
ABSTRACT

Background:

Vaccine effectiveness against SARS-CoV-2 infection has been somewhat limited due to the widespread dissemination of the Omicron variant, its subvariants, and the immune response dynamics of the naturally infected with the virus.

Methods:

Twelve subjects between 3-17 years old (yo), vaccinated with two doses of CoronaVac®, were followed and diagnosed as breakthrough cases starting 14 days after receiving the second dose. Total IgGs against different SARS-CoV-2 proteins and the neutralizing capacity of these antibodies after infection were measured in plasma. The activation of CD4+ and CD8+ T cells was evaluated in peripheral blood mononuclear cells stimulated with peptides derived from the proteins from the wild-type (WT) virus and Omicron subvariants by flow cytometry, as well as different cytokines secretion by a Multiplex assay.

Results:

2 to 8 weeks post-infection, compared to 4 weeks after 2nd dose of vaccine, there was a 146.5-fold increase in neutralizing antibody titers against Omicron and a 38.7-fold increase against WT SARS-CoV-2. Subjects showed an increase in total IgG levels against the S1, N, M, and NSP8 proteins of the WT virus. Activated CD4+ T cells showed a significant increase in response to the BA.2 subvariant (p<0.001). Finally, the secretion of IL-2 and IFN-γ cytokines showed a discreet decrease trend after infection in some subjects.

Conclusion:

SARS-CoV-2 infection in the pediatric population vaccinated with an inactivated SARS-CoV-2 vaccine produced an increase in neutralizing antibodies against Omicron and increased specific IgG antibodies for different SARS-CoV-2 proteins. CD4+ T cell activation was also increased, suggesting a conserved cellular response against the Omicron subvariants, whereas Th1-type cytokine secretion tended to decrease. Clinical Trial Registration clinicaltrials.gov #NCT04992260.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: CD4-Positive T-Lymphocytes / Antibodies, Neutralizing / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Antibodies, Viral Limits: Adolescent / Child / Child, preschool / Female / Humans / Male Language: En Journal: Front Immunol Year: 2024 Document type: Article Affiliation country: Chile Country of publication: Switzerland

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: CD4-Positive T-Lymphocytes / Antibodies, Neutralizing / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Antibodies, Viral Limits: Adolescent / Child / Child, preschool / Female / Humans / Male Language: En Journal: Front Immunol Year: 2024 Document type: Article Affiliation country: Chile Country of publication: Switzerland